TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Anteris Technologies Global Corp. Common Stock (AVR)

Healthcare Medical Instruments & Supplies
7.80 $
-4.9% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Anteris Technologies Global Corp. Common Stock.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 18 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Trading Day

Previous Close
8.20$
Open
8.30$
Day High
8.40$
Day Low
7.70$
Volume
1,034,826shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
3.10 $ 10.60 $
08/01/2025 07/06/2026

Current price 7.80 $ — 63% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
0.8$B
Shares Outstanding
97Mio.
Float
62.0%
Beta
0.7

Performance

Perf. 1M
11.50%
Perf. 3M
88.40%
Perf. 6M
80.80%
YTD Performance (%)
106.00%
52-Week-High Distance
-6.4%
Perf. 1Y
144.24%
Perf. 5Y
73.33%
Perf. Since Inception
30.67%

Technical Indicators

MA 38 Days
9.20$
MA 50 Days
9.20$
MA 200 Days
6.40$
RSI (14)
36.5
Volatility 30 Days
51.4%
Volatility 250 Days
74.3%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
0.0
PEG
P/B
P/S
421.7
EV/EBITDA
0.0
Price/FCF

Profitability

Gross Margin
74.3%
EBIT Margin
Net Margin
0.0%
Return on Equity
-59.2%
Return on Assets
-34.0%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
fortress balance sheet
Altman Z″
20.74
Piotroski
4 out of 9

Growth

Sales Growth Last Quarter
-11.20%
EPS Growth Last Quarter
0.00%
Sales Growth (Year)
-29.23%
Forward Sales Growth
43.94%
Forward EPS Growth
9.30%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
2
Top 10%
RS Rating
94
EPS Rating
42
Piotroski
4 out of 9
Fundamental Rating
D (31 out of 100)
fortress balance sheet
Altman Z″
20.74

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 7.80 $
Price Target (average) 15.33 $

The price target sits 96.5% above the current price.

Consensus
Strong Sell
Analyst Ratings
4
Distribution of Recommendations
Strong Buy 3
Buy 1
Hold 0
Sell 0
Strong Sell 0

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 -1.08 -1.18 – -0.95 14 57.7% 3
12/31/2027 -0.98 -1.03 – -0.92 20 9.3% 3

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

10. Aug 2026 · Q2 2026
Expected Earnings per Share
-0.22 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 0.5 $M Q4 2025: Q1 · 0.6 $M Q1 2025: Q2 · 0.6 $M Q2 2025: Q3 · 0.4 $M Q3 2025: Q4 · 0.3 $M Q4 2026: Q1 · 0.5 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.20 1 -1.50 -3,614.70 -18 -19
2025: Q1 -0.22 1 -27.40 -3,932.40 -22 -22
2025: Q2 -0.21 1 -2.20 -3,371.20 -20 -20
2025: Q3 -0.23 0 -44.20 -5,185.10 -18 -19
2025: Q4 -0.30 0 -42.20 -9,420.00 -19 -19
2026: Q1 -0.24 1 -11.20 -4,660.70 -29 -29
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2020 5 -13 -12 -0.33 -11 2 10
2021 6 -17 -17 -0.48 -14 11 21
2022 3 -31 -31 -0.85 -29 9 16
2023 3 -48 -46 -1.28 -35 19 31
2024 3 -78 -76 -3.77 -61 63 81
2025 2 -94 -94 -3.99 -78 0 23

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

Anteris Technologies Global Corp., ein Unternehmen für strukturelle Herzerkrankungen, entwickelt und vermarktet minimalinvasive Medizinprodukte zur Behandlung von Herzklappenerkrankungen.

Employees174
HeadquartersToowong, QLD
AddressToowong Tower, 4066 Toowong, Australia
Phone61 7 3152 3200
Websiteanteristech.com
IPO Date13. Dec 2024
ISINUS03675P1021

Management

Management
Name Title Birth Year
Wayne Geoffrey Paterson Vice Chairman & CEO 1967
David St. Denis President & Director 1969
Matthew McDonnell Chief Financial Officer 1974
Chris Meduri M.D., M.P.H. Chief Medical Officer & Member of Medical Advisory Board

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
30. Jul 2026 L1 Capital Pty Ltd 10% Owner Sell 558,633 8.20 4,580,791
29. Jul 2026 L1 Capital Pty Ltd 10% Owner Sell 155,505 8.04 1,250,260
28. Jul 2026 L1 Capital Pty Ltd 10% Owner Sell 208,731 8.09 1,688,634
27. Jul 2026 L1 Capital Pty Ltd 10% Owner Sell 232,817 8.19 1,906,771
24. Jul 2026 L1 Capital Pty Ltd 10% Owner Sell 23,000 8.13 186,990

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?